FDA Undermined Switch Process With Past Plan B Deviations – CRR
This article was originally published in The Tan Sheet
Executive Summary
The Center for Reproductive Rights says FDA should not be granted a stay of a judge’s order to approve OTC emergency contraceptives. CRR says FDA forfeited the authority to argue in defense of the regulatory approval process given its previous departures from that process in reviewing Plan B One-Step.
You may also be interested in...
NaZura’s Lovidia Weight-Loss Supplement Strategy Focused On Brand Building
NaZura BioHealth, spun out from Elcelyx Therapeutics, will market its Lovidia weight-loss product in 2014 when it launches into the direct-response channel, before potential suitors get serious about acquiring the brand.
NaZura’s Lovidia Weight-Loss Supplement Strategy Focused On Brand Building
NaZura BioHealth, spun out from Elcelyx Therapeutics, will market its Lovidia weight-loss product in 2014 when it launches into the direct-response channel, before potential suitors get serious about acquiring the brand.
Certain Dri Antiperspirant Sweats It Out Against Big Players
With a thicker, “drip-free” reformulation of Certain Dri launching in January 2014, DSE Healthcare Solutions hopes its clinical-strength roll-on antiperspirant will appeal to more consumers with hyperhidrosis as well as those concerned about but not diagnosed with excessive perspiration.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: